Hellman Jordan Management CO Inc Vertex Pharmaceuticals Inc Transaction History

Hellman Jordan Management CO Inc

$58.9 Million
Q4 2022

A detailed history of Hellman Jordan Management CO Inc transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Hellman Jordan Management CO Inc holds 5,349 shares of VRTX stock, worth $2.14 Million. This represents 2.62% of its overall portfolio holdings.

Number of Shares

5,349

Previous 4,641 15.26%

Holding current value

$2.14 Million

Previous $1.34 Million 14.96%

% of portfolio

2.62%

Previous 2.33%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Jan 20, 2023	BUY	$285.76 - $321.48 $202,318 - $227,607	708 Added 15.26%	5,349 $1.55 Million
Q3 2022 Oct 13, 2022	SELL	$273.83 - $305.53 $550,672 - $614,420	-2,011 Reduced 30.23%	4,641 $1.34 Million
Q2 2022 Sep 27, 2022	BUY	$234.96 - $292.55 $419,638 - $522,494	1,786 Added 36.7%	6,652 $1.87 Million
Q1 2022 Jun 16, 2022	SELL	$221.42 - $260.97 $646,767 - $762,293	-2,921 Reduced 37.51%	4,866 $1.27 Million
Q4 2021 Jan 26, 2022	SELL	$177.01 - $223.45 $544,128 - $686,885	-3,074 Reduced 28.3%	7,787 $1.71 Million
Q3 2021 Oct 26, 2021	BUY	$181.39 - $202.99 $606,930 - $679,204	3,346 Added 44.52%	10,861 $1.97 Million
Q2 2021 Jul 21, 2021	BUY	$187.49 - $221.1 $2,062 - $2,432	11 Added 0.15%	7,515 $1.52 Million
Q1 2021 May 06, 2021	BUY	$207.02 - $241.31 $1.36 Million - $1.59 Million	6,580 Added 712.12%	7,504 $1.61 Million
Q4 2020 Jan 29, 2021	BUY	$207.01 - $276.09 $14,490 - $19,326	70 Added 8.2%	924 $218,000
Q3 2020 Nov 12, 2020	BUY	$255.65 - $303.1 $4,601 - $5,455	18 Added 2.15%	854 $232,000
Q2 2020 Jul 21, 2020	SELL	$225.48 - $295.8 $1,352 - $1,774	-6 Reduced 0.71%	836 $243,000
Q1 2020 May 28, 2020	BUY	$199.77 - $247.81 $168,206 - $208,656	842 New	842 $200,000

Others Institutions Holding VRTX

# of Institutions

1,725

Shares Held

221M

Call Options Held

1.58M

Put Options Held

1.36M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $103B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Hellman Jordan Management CO Inc , based on Form 13F filings with the SEC.

News

Stay updated on Hellman Jordan Management CO Inc with notifications on news.

Account

Hellman Jordan Management CO Inc Vertex Pharmaceuticals Inc Transaction History